SciSparc Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, seeks to have the registration become effective on March 6, 2024, at 4:15 p.m. Eastern Time. This request, if granted, would allow SciSparc to proceed with its proposed public offering of securities as detailed in the Registration Statement. The company has confirmed its understanding of and commitment to its responsibilities under the Securities Act of 1933 in relation to the offering. SciSparc has requested both telephonic and written confirmation of the Registration Statement's effectiveness from the SEC.

SciSparc Ltd., a biopharmaceutical company, has formally requested the Securities and Exchange Commission (SEC) to accelerate the effectiveness of its Registration Statement on Form F-1. The company, based in Tel Aviv, Israel, seeks to have the registration become effective on March 6, 2024, at 4:15 p.m. Eastern Time. This request, if granted, would allow SciSparc to proceed with its proposed public offering of securities as detailed in the Registration Statement. The company has confirmed its understanding of and commitment to its responsibilities under the Securities Act of 1933 in relation to the offering. SciSparc has requested both telephonic and written confirmation of the Registration Statement's effectiveness from the SEC.